Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Select coverage from IAS 2017 Conference is included below:

Why is the Population-based HIV Impact Assessment Project Important?
Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.
Is Cabotegravir a Gender-Neutral PrEP Medication?
Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.
What is the Population-based HIV Impact Assessment Project?
Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).
How is Janssen's New HIV-1 Vaccine Regimen Unique?
Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
What Makes Cabotegravir a Unique Medication for HIV?
Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.
New Formulation of Raltegravir HD Explained
Pedro Cahn, MD, explains the new formulation of raltegravir HD.
Treating HIV Today vs the 1980s: One Doctor's Perspective
Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.
Mother-to-Child Transmission of HIV Remains a Significant Burden
Lynne Mofenson, MD, shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.
FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x